Genscript Biotech Corporation Logo

Genscript Biotech Corporation

GNNSF

(1.5)
Stock Price

1,25 USD

-8.16% ROA

-13.58% ROE

-10.91x PER

Market Cap.

2.940.298.200,00 USD

28.89% DER

0% Yield

-17.53% NPM

Genscript Biotech Corporation Stock Analysis

Genscript Biotech Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Genscript Biotech Corporation Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (35%), which means it has a small amount of debt compared to the ownership it holds

2 Revenue Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

3 Assets Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

4 ROE

The stock's ROE indicates a negative return (-24%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-9%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 PBV

The stock's elevated P/BV ratio (5.9x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Genscript Biotech Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Genscript Biotech Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Buy
4 Stoch RSI Buy

Genscript Biotech Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Genscript Biotech Corporation Revenue
Year Revenue Growth
2013 60.104.000
2014 69.994.000 14.13%
2015 86.709.000 19.28%
2016 114.735.000 24.43%
2017 152.649.000 24.84%
2018 231.017.000 33.92%
2019 273.354.000 15.49%
2020 390.846.000 30.06%
2021 511.062.000 23.52%
2022 625.698.000 18.32%
2023 841.493.075 25.64%
2024 2.247.912.428 62.57%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Genscript Biotech Corporation Research and Development Expenses
Year Research and Development Expenses Growth
2013 6.064.000
2014 5.589.000 -8.5%
2015 7.111.222 21.41%
2016 9.478.364 24.97%
2017 17.998.452 47.34%
2018 74.076.000 75.7%
2019 186.022.000 60.18%
2020 263.401.000 29.38%
2021 358.401.000 26.51%
2022 390.096.000 8.12%
2023 433.839.597 10.08%
2024 946.558.572 54.17%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Genscript Biotech Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
2013 16.376.999
2014 21.446.000 23.64%
2015 28.535.000 24.84%
2016 30.429.000 6.22%
2017 40.094.000 24.11%
2018 40.582.000 1.2%
2019 55.256.000 26.56%
2020 90.341.000 38.84%
2021 134.508.000 32.84%
2022 182.462.000 26.28%
2023 213.441.000 14.51%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Genscript Biotech Corporation EBITDA
Year EBITDA Growth
2013 13.084.000
2014 13.148.000 0.49%
2015 19.493.000 32.55%
2016 37.909.000 48.58%
2017 44.463.000 14.74%
2018 35.368.000 -25.72%
2019 -91.457.000 138.67%
2020 -173.743.000 47.36%
2021 -449.270.000 61.33%
2022 -371.790.000 -20.84%
2023 -316.900.657 -17.32%
2024 -193.673.224 -63.63%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Genscript Biotech Corporation Gross Profit
Year Gross Profit Growth
2013 38.134.000
2014 44.098.000 13.52%
2015 57.078.000 22.74%
2016 76.229.000 25.12%
2017 104.591.000 27.12%
2018 158.539.000 34.03%
2019 180.290.000 12.06%
2020 255.893.000 29.54%
2021 303.484.000 15.68%
2022 304.083.000 0.2%
2023 410.511.148 25.93%
2024 1.229.271.988 66.61%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Genscript Biotech Corporation Net Profit
Year Net Profit Growth
2013 6.000.000
2014 6.175.000 2.83%
2015 17.504.000 64.72%
2016 26.170.000 33.11%
2017 26.123.000 -0.18%
2018 21.216.000 -23.13%
2019 -96.912.000 121.89%
2020 -204.945.000 52.71%
2021 -347.865.000 41.08%
2022 -226.851.000 -53.35%
2023 -95.700.368 -137.04%
2024 -701.217.528 86.35%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Genscript Biotech Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2013 0
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Genscript Biotech Corporation Free Cashflow
Year Free Cashflow Growth
2013 3.606.000
2014 4.689.000 23.1%
2015 12.198.000 61.56%
2016 24.294.000 49.79%
2017 -10.603.000 329.12%
2018 215.803.000 104.91%
2019 -148.491.000 245.33%
2020 -278.840.000 46.75%
2021 -274.187.000 -1.7%
2022 -323.864.000 15.34%
2023 -441.700.946 26.68%
2024 -18.570.061 -2278.56%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Genscript Biotech Corporation Operating Cashflow
Year Operating Cashflow Growth
2013 12.024.000
2014 12.206.000 1.49%
2015 19.636.000 37.84%
2016 33.275.000 40.99%
2017 21.368.000 -55.72%
2018 295.412.000 92.77%
2019 -29.955.000 1086.19%
2020 -151.093.000 80.17%
2021 -136.790.000 -10.46%
2022 -120.292.000 -13.71%
2023 -283.618.977 57.59%
2024 81.981.565 445.95%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Genscript Biotech Corporation Capital Expenditure
Year Capital Expenditure Growth
2013 8.418.000
2014 7.517.000 -11.99%
2015 7.438.000 -1.06%
2016 8.981.000 17.18%
2017 31.971.000 71.91%
2018 79.609.000 59.84%
2019 118.536.000 32.84%
2020 127.747.000 7.21%
2021 137.397.000 7.02%
2022 203.572.000 32.51%
2023 158.081.969 -28.78%
2024 100.551.626 -57.21%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Genscript Biotech Corporation Equity
Year Equity Growth
2013 52.563.000
2014 61.747.000 14.87%
2015 149.248.000 58.63%
2016 184.021.000 18.9%
2017 228.319.000 19.4%
2018 493.299.000 53.72%
2019 372.298.000 -32.5%
2020 815.591.000 54.35%
2021 1.092.955.000 25.38%
2022 1.362.668.000 19.79%
2023 2.086.044.000 34.68%
2023 2.043.799.277 -2.07%
2024 1.823.443.427 -12.08%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Genscript Biotech Corporation Assets
Year Assets Growth
2013 83.835.000
2014 92.380.000 9.25%
2015 182.074.000 49.26%
2016 226.032.000 19.45%
2017 504.264.000 55.18%
2018 916.976.000 45.01%
2019 889.411.000 -3.1%
2020 1.447.406.000 38.55%
2021 2.232.770.000 35.17%
2022 2.546.383.000 12.32%
2023 3.384.321.000 24.76%
2023 3.386.382.877 0.06%
2024 3.330.472.353 -1.68%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Genscript Biotech Corporation Liabilities
Year Liabilities Growth
2013 29.885.000
2014 30.633.000 2.44%
2015 32.826.000 6.68%
2016 42.011.000 21.86%
2017 275.945.000 84.78%
2018 423.677.000 34.87%
2019 517.113.000 18.07%
2020 631.815.000 18.15%
2021 1.139.815.000 44.57%
2022 1.183.715.000 3.71%
2023 1.298.277.000 8.82%
2023 1.325.872.135 2.08%
2024 1.487.503.103 10.87%

Genscript Biotech Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.77
Net Income per Share
-0.13
Price to Earning Ratio
-10.91x
Price To Sales Ratio
1.81x
POCF Ratio
-11.83
PFCF Ratio
-4.94
Price to Book Ratio
2.44
EV to Sales
1.83
EV Over EBITDA
-6.67
EV to Operating CashFlow
-11.9
EV to FreeCashFlow
-5.01
Earnings Yield
-0.09
FreeCashFlow Yield
-0.2
Market Cap
2,94 Bil.
Enterprise Value
2,98 Bil.
Graham Number
1.29
Graham NetNet
0.28

Income Statement Metrics

Net Income per Share
-0.13
Income Quality
0.92
ROE
-0.2
Return On Assets
-0.05
Return On Capital Employed
-0.12
Net Income per EBT
0.57
EBT Per Ebit
0.91
Ebit per Revenue
-0.34
Effective Tax Rate
-0.04

Margins

Sales, General, & Administrative to Revenue
0.1
Research & Developement to Revenue
0.48
Stock Based Compensation to Revenue
0.03
Gross Profit Margin
0.54
Operating Profit Margin
-0.34
Pretax Profit Margin
-0.31
Net Profit Margin
-0.18

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.12
Free CashFlow per Share
-0.28
Capex to Operating CashFlow
-1.37
Capex to Revenue
0.21
Capex to Depreciation
2.6
Return on Invested Capital
-0.38
Return on Tangible Assets
-0.08
Days Sales Outstanding
53.76
Days Payables Outstanding
27.09
Days of Inventory on Hand
23.44
Receivables Turnover
6.79
Payables Turnover
13.47
Inventory Turnover
15.57
Capex per Share
0.16

Balance Sheet

Cash per Share
0,89
Book Value per Share
0,87
Tangible Book Value per Share
0.87
Shareholders Equity per Share
0.57
Interest Debt per Share
0.19
Debt to Equity
0.29
Debt to Assets
0.11
Net Debt to EBITDA
-0.09
Current Ratio
4.12
Tangible Asset Value
1,84 Bil.
Net Current Asset Value
0,71 Bil.
Invested Capital
2496383630
Working Capital
1,66 Bil.
Intangibles to Total Assets
0
Average Receivables
0,27 Bil.
Average Payables
0,05 Bil.
Average Inventory
52083618
Debt to Market Cap
0.12

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Genscript Biotech Corporation Dividends
Year Dividends Growth
2017 0

Genscript Biotech Corporation Profile

About Genscript Biotech Corporation

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.

CEO
Ms. Weihui Shao
Employee
7.284
Address
Jiangning Science Park
Nanjing, 211100

Genscript Biotech Corporation Executives & BODs

Genscript Biotech Corporation Executives & BODs
# Name Age
1 Ms. Ye Wang M.S.
Co-Founder, President & Executive Director
70
2 Dr. Luquan Wang
Co-Founder & Non-Executive Director
70
3 Mr. Shiniu Wei
Chief Financial Officer
70
4 Dr. Fangliang Zhang EMBA, Ph.D.
Co-Founder & Executive Director
70
5 Dr. Li Zhu Ph.D.
Chief Strategy Officer & Executive Director
70
6 Ms. Aylin Kosova Bilgin
Chief Marketing Officer for GenScript Life Science Group
70
7 Mr. Jiange Meng
Executive Chairman
70
8 Ms. Weihui Shao
Chief Executive Officer & Chief Operating Officer
70

Genscript Biotech Corporation Competitors